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Imepitoin is a low affinity partial agonist for the benzodiazepine binding site of
γ-aminobutyric acid (GABAA) receptors, and is currently used as an antiepileptic in
dogs. Here we tested imepitoin for anxiolytic properties. In an in vitro model, imepitoin
was capable of preventing the effect of corticotrophin releasing factor (CRF) on locus
coeruleus neurons without suppressing the basal activity of these cells, an activity which
is suggestive for an anti-stress effect of imepitoin. In addition, we applied a battery of
standard rodent preclinical tests for anxiety behavior including elevated plus mazes in
mice and rats, light-dark-box in mice and rats, social interaction test in rats, or the Vogel
conflict test in rats. In all models, the observed profile of imepitoin appeared similar to
benzodiazepines and typical for anxiolytic drugs. We also observed anxiolytic activity
in dogs in a provoked open field sound-induced fear model, where reactions to noises
were elicited by a sound recording of thunderstorms. Imepitoin caused an increase
in locomotion measured in distance traveled and an ameliorating effect on cortisol
levels in response to thunderstorm noises. For comparison, dexmedetomidine caused
a decrease in locomotion and had no effect on cortisol. In all animal models the doses
needed for an anxiolytic effect were not associated with sedation. In rodents, there was
at least a factor of 10 between anxiolytic doses and doses with mild signs of sedation. In
summary, imepitoin showed similar anxiolytic activities as benzodiazepines but without
producing the known adverse reactions of benzodiazepines such as sedation.
Keywords: anxiolytic, imepitoin, in vitro, in vivo, dog, mouse, rat
INTRODUCTION
Physiologically, anxiety is an important protective mechanism to increase vigilance, which allows
an individual to react to a perceived present or anticipated threat with an appropriate behavior (e.g.,
flight). When occurring at inappropriate times or to an excessive degree, anxiety can be described as
pathological both in humans and in animals (Stein and Steckler, 2010). Despite the high prevalence
of these conditions current treatment options are limited (Griebel and Holmes, 2013).
Abbreviations: SD, standard deviation.
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Since full agonist benzodiazepines are known to be potent
anxiolytics, it was hypothesized that partial agonists could also
potentially retain anxiolytic activity, but without producing
the known adverse reactions of benzodiazepines such as
sedation, muscle relaxation, and, upon repeated administration,
development of tolerance. (Skolnick, 2012).
Imepitoin is a centrally acting drug and a low affinity
partial agonist for the BZD binding site of γ-aminobutyric
acid (GABAA) receptors (Rundfeldt and Loscher, 2014). The
compound potentiates the amplitude of GABA evoked chloride
(Cl-) currents by acting at the BZD recognition site of the
GABAA receptor, creating a higher affinity between GABA and its
receptor sites. Imepitoin has a lower affinity for the BZD binding
site of GABAA receptors than BZD receptor agonists such as
diazepam (DZP). Additionally it exhibits a weak calcium (Ca2±)
channel blocking effect. Currently imepitoin is in veterinary use
for the treatment of idiopathic epilepsy in dogs (Rundfeldt and
Loscher, 2014).
Anxiolytic effects in the GABA-ergic pathway are mediated
by α2- and α5 and possibly a3- subunit containing GABAA-
receptors (Löw et al., 2000; Whiting, 2006). Previous work
demonstrated that imepitoin is active on these receptor subtypes
(Sigel et al., 1998).
Here we report results from preclinical studies examining
anxiolytic effects of imepitoin. Based on imepitoin’s mode of
action, we examine whether imepitoin had similar effects as
benzodiazepines in commonly used models.
MATERIALS AND METHODS
Locus Coeruleus (LC) Neuronal Cell
Culture
Single locus coeruleus (LC) neurons in 200 µm thick brainstem
slices were visualized with infrared videomicroscopy and
patch-clamped in the whole-cell configuration as described
elsewhere (Liss et al., 1999). These cells exhibit a spontaneous
pace maker activity which can be reversibly potentiated with
corticotrophin releasing factor (CRF). Drugs were directly
applied onto the brain slices in concentrations of 0.1, 1, and
10 µM.
Animals
All experiments were carried out in accordance with the
principles of the Basel Declaration and according to applicable
legislation [i.e., for example European directive on the protection
of animals used for scientific purposes (2010/63/EU)]. If
applicable, they were approved by the relevant authorities or
Institutional Animal Care and Use Committees (IACUC).
Wistar rats (Crl WI BR, 270–330 g), CD rats (Crl 240–325 g)
or Crl:NMRI BR mice (25–35 g) were used in the rodent
experiments. Standard food (e.g., SNIFF Spezialdiäten GmbH,
Soest, Germany) and water were provided ad libitum, and
animals were housed in groups under a 12 h light and dark cycle.
Beagle dogs (Vivocore Inc., Fergus, ON, Canada) were group
housed in pens of four with a hide box, a raised resting platform,
various toys and background music (<85 decibels). A standard
commercial diet once a day and water ad libitum was offered, and
12 h light and dark cycle was maintained.
The experimental setups were cleaned after each test (e.g.,
wiped with alcohol).
Drug Preparation and Administration
For intraperitoneal and oral administration in rodents, all test
substances were suspended in 5-hydroxyethylcellulose (0.5%
in water), with plain 5-hydroxyethylcellulose (0.5% in water)
solution serving as placebo. Presumably non-sedative doses
for benzodiazepines were chosen, in consideration of the low
oral bioavailability of benzodiazepines in rodents compared to
humans and other species. In the dog study, tablets identical to
the commercial presentation (PexionTM; Boehringer Ingelheim
Vetmedica GmbH, Ingelheim, Germany) were used, and
baseline observations under no treatment were used as control.
Administration of a single oral dose (20 mg/kg imepitoin) to dogs
was performed 138 min before noise exposure, i.e., to achieve
maximum plasma concentrations during the noise exposure
(Rundfeldt et al., 2014). Dexmedetomidine as oromucosal gel
(SileoTM; Orion Pharma, Espoo, Finland) was administered
60 min before testing at a dose of 125 µg/m2 according to the
manufacturer’s instructions.
Elevated Maze in Rodents
For rats, the maze consisted of three open (35× 10 cm) and three
closed (35× 10× 15 cm) arms extending from a central platform.
In mice, the maze consisted of two open (17.5× 7.8 cm) and two
closed (19× 8× 15 cm) arms extending from a central platform,
placed 80 cm off floor (Walf and Frye, 2007).
In both cases, adaptation to the test room was ensured by 24 h
housing in the test room and experiments were conducted under
controlled light conditions (12 h on: 12 h off light dark cycle;
lights on at 07.00 h, with normal ambient light). The movements
of the animals were recorded for 5 min with a video camera for
subsequent analysis. The number of entries in the open arms, the
number of entries in the closed arms and the time spent in the
open arms were measured (Walf and Frye, 2007).
Doses of imepitoin (1–30 mg/kg i.p.), alongside the
benzodiazepines diazepam (0.25–2.0 mg/kg), triazolam
(0.003–1.0 mg/kg), and alprazolam (0.1–1.0 mg/kg),
administered 30 min before test, and pentetrazol (10.0 and
20.0 mg/kg) administered 5 min before test, were given to ten
rats per group. In mice (n = 10 per group) i.p. doses of imepitoin
(doses from 3.13 to 200 mg/kg), were compared to diazepam
(0.2–12.5 mg/kg) and placebo administered 30 min before the
test and p.o. administration of imepitoin 30 mg/kg 2 h before
testing.
Light-Dark-Box in Rodents
A two compartment box (each compartment 22 × 22 × 22 cm)
was used in this test, with one light and open and the other dark
and closed. Both compartments were connected with an open
door. Animals were placed in the light part and observed for
5 min. Latency to first cross in the dark part, total time spent
in light part and the number of crosses from one part into the
other was measured (Bourin and Hascoet, 2003). Along with a
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placebo group, imepitoin was tested at different doses between 1
and 30 mg/kg and diazepam at doses between 1 and 10 mg/kg and
placebo (n = 10 per group).
Social Interaction Test in Rats
A pair of rats that were unfamiliar to each other was placed
into an arena, one animal at each end (File and Hyde, 1978).
Both rats were treated with the same test substance and dose.
The arena was a circular open field apparatus made of white
plastic, approximately 1 m in diameter enclosed by 25 cm high
walls. It was covered by a muslin cloth and illuminated with
ambient light. Behavior was scored at 15 s intervals over a 10 min
period. The score values were 0 (No interaction), 1 (Passive
interaction, e.g., lying in contact), 2 (one-way investigative
interaction, e.g., 1 rat following or sniffing the other), 3 (one-way
active interaction, e.g., 1 rat grooming the other), 4 (two-way
investigative interaction, e.g., both rats mutually rat following or
sniffing the other), or 5 (two-way active interaction, e.g., both
rats grooming the other, playing together, etc.). The test was
performed in five groups with nine pairs each with imepitoin
(doses 3, 10, and 30 mg/kg), diazepam (5 mg/kg), and placebo.
Conflict-Based Tests in Rodents
The Geller conflict test was performed as described elsewhere
(Geller and Seifter, 1960). Rats were trained in a standard Skinner
box (23 × 21 × 18 cm; MED Associates) that lever-pressing
results in a food reward (food pellets 45 mg). The lever was
located on the right of the food pellet dispenser, and above a white
and a red signal light were installed. For further training and test,
periods of responding by lever pressing to get food pellets on a
variable interval schedule (mean value 15 s) indicated by a white
light are interrupted by periods where, in the presence of a red
signal light, food can be obtained more frequently (mean value
10 s) but accompanied by mild footshocks (0.4 mA, 0.5 s). Each
lever pressing under white light (i.e., without electric shock) was
defined as unpunished response, while those under red light were
punished responses. The number of unpunished and punished
responses was measured. Groups of eight rats received either
imepitoin (3–30 mg/kg), diazepam (16 mg/kg), chlordiazepoxid
(16 mg/kg), or placebo.
Briefly, the Vogel conflict test (Millan and Brocco, 2003)
consisted of a Plexiglas conflict test box (30 × 23 × 19 cm).
A water bottle was placed outside the box, with a stainless steel
spout extending into the box about 2 cm above floor level.
After an unpunished training session of 10 min, the second
session lasted 3 min and was performed on the next day. In that
session drinking was punished for 2-s periods, followed by 3 s
unpunished periods. The number of electric shocks (0.5 mA)
received within the 3 min test period was recorded. Groups
of 12 rats received either imepitoin (1–50 mg/kg), diazepam
(0.3–30 mg/kg), or placebo.
The four-plate apparatus used in mice is a rectangular
chamber (23 × 18 × 30 cm) whose floor is divided into four
equally sized rectangular copper plates, as described elsewhere
(Jones et al., 1994). The test was divided into two parts, 20 s of free
exploration, followed by a second phase in which each crossing
between the plates was punished with a mild (1.0 mA) and brief
(0.1 s) electric shock to the feet administered by the experimenter
using a hand held button. The measure was the number of
shocks received in 1 min period. Groups of 10 mice received
either imepitoin (3.13–200 mg/kg), diazepam (0.2–12.5 mg/kg),
or placebo.
Noise-Induced Model of Fear and
Anxiety in Dogs
For this test, subjects were placed in an open field arena, which
is a room 2.45 × 2.75 m for 9 min (Araujo et al., 2013). It
was hypothesized that if a drug has anxiolytic properties then it
should result in a shift from fearful flight to behavioral inhibition
or non-anxious “rumination” (McNaughton and Gray, 2000) and
an increase in exploratory behavior. This would be manifest as
an increase in behavioral pauses, but an increase in behavioral
activity (since exploratory behavior is more elaborate than flight
behavior), without an increase in cortisol in cortisol reactive
subjects (raised cortisol being indicative of increased arousal
associated with fear response in this context). Animal behavior
was recorded via video and distance traveled, as well as frequency
and duration of inactivity (defined as the animal sitting or lying
down, or not exhibiting any overt behavior) were measured using
Ethovision XT (Noldus Information Technology, Netherlands).
Blood samples for cortisol measurements were collected 1 h
before and 5 min after the test.
For training, each subject was allowed to freely explore
the room over a 9-min period during which no stimuli were
provided. For baseline and test measurements, a thunder track
played over a stereo system with a decibel range of 61–85 db for
3 min of the 9 min period (minutes 4–6).
Beagle dogs (both gender, age 1–6 years) were first grouped
based on their cortisol response into cortisol responders (at
least a 9% increase in blood cortisol from the baseline) and
non-responders, and secondly on their activity responses as
hyperactive responders (≥10% increase in activity ratio between
minutes 1–3 and minutes 4–6 from training to baseline
thunderstorm) and hypoactive responders (<10% increase).
In two independent experiments, 24 dogs received imepitoin
and 25 dogs dexmedetomidine. Baseline values from the
respective experiment values served as control. Drugs were
administered as a single dose before the test (imepitoin 135 min,
dexmedetomidine 60 min before thunder test).
Statistics
Treatment allocation was performed randomly and remained
completely blinded for the examiners. Data are presented
descriptively as mean and SD, or for ordinal values as median.
Hypothesis tests were always performed against placebo control
or baseline, using appropriate 2-sided statistical tests for
significant differences (p < 0.05; mainly Mann–Whitney U or
t-Test for two groups, Dunnett’s procedure for more than two
groups).
For logistical reasons, most of the animal tests were set up as a
series of experiments. A control group was included in each single
experiment, and wherever possible, all doses of a test product
were tested in the same experiment.
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RESULTS
Effect on Basal and CRF-Induced Activity
in the Locus Coeruleus (LC) Neurons
The in vitro study indicated that imepitoin (at doses of 1 and
10 µM) acts to decrease neuronal activity induced by CRF but not
the basal (spontaneous pacemaker) activity in mouse LC neurons.
The half-maximal inhibition could be determined to 60 nM for
diazepam and 520 nM for imepitoin, respectively (Figure 1).
Elevated Maze in Rodents
The influence of imepitoin on anxiety related behavior of rats
(n = 10 per group) was investigated in an elevated maze. At doses
of 10 and 30 mg/kg i.p. (administered 30 min before test) the
percentage of entries in the open arms and the percentage of time
spent in the open arms were significantly increased compared to
placebo. The doses 1 and 3 mg/kg i.p. did not show significant
differences to placebo (Figure 2A, Table 1, and Supplementary
Table 1).
For comparison the benzodiazepines diazepam (0.25, 0.5,
1.0, and 2.0 mg/kg), triazolam (0.003, 0.01, 0.03, 0.1, 0.3, and
1.0 mg/kg), and alprazolam (0.1, 0.3, and 1.0 mg/kg) were tested
(all i.p. administered 30 min before test). Diazepam significantly
increased the percentage of time spent in the open arms (Table 1)
at doses of 1 and 2 mg/kg compared to placebo. For triazolam
the percentage of entries was significantly increased for doses
of 0.03 mg/kg and above (Table 1), and the time spent in the
open arm was significantly increased for 0.03 and 0.1 mg/kg,
while in higher doses sedative effects were observed. Alprazolam
significantly increased the percentage of time spent in the open
arms at 0.3 mg/kg (Table 1), while there were sedative effects at
the high dose.
In contrast the anxiogenic compound pentetrazol
(10.0/20.0 mg/kg administered 5 min before test) was tested. The
higher dose decreased the percentage of time spent in the open
arms compared to placebo (Table 1).
In mice (n = 10 per group) the elevated maze model was
used with various i.p. doses of imepitoin (3.13, 6.25, 12.5, 25, 50,
100, and 200 mg/kg), diazepam (0.2, 0.39, 0.78, 1.56, 3.13, 6.25,
and 12.5 mg/kg), and placebo administered 30 min before the
test. After low dose i.p. administration of imepitoin (3.13 mg/kg)
we observed an increased number of entries into the open
arm (Table 1). All other variables and doses did not reveal
significant treatment effects (Supplementary Table 1). In the
highest administered doses of imepitoin (100 and 200 mg/kg)
slight locomotor sedation was observed in mice. Diazepam
increased the number of entries into the open arm with a minimal
effective dose of 0.39 mg/kg (Table 1). At high doses of diazepam
(≥6.25 mg/kg) there were indications of sedative effects. At doses
FIGURE 1 | Corticotrophin Releasing Factor (CRF, 200 nM) induced discharge of mouse locus coeruleus neurons are reduced by both Diazepam (doses 0.1; 1 and
10 µM) and imepitoin (doses 1 and 10 µM) with a half maximal inhibition in the range of 60 and 520 nM, respectively (n = 3 per concentration).
Frontiers in Pharmacology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 1225
fphar-09-01225 October 30, 2018 Time: 15:20 # 5
Engel et al. Imepitoin in Models of Anxiety
FIGURE 2 | (A) Imepitoin at doses of 10.0 and 30.0 mg/kg shows significantly increased percentage of time spent in the open arm of the elevated maze in rats
compared to placebo control (marked as “C”). Similar effects were observed with different benzodiazepines, and the anxiogenic substance penterazol led to a
decreased percentage. (Series of 9 experiments, n = 10 per group) (B) In rats, the total amount of time spent in the light part of the light-dark-box was significantly
increased in doses above 1.0 mg/kg imepitoin compared to control (0 mg/kg) (Series of three experiments, n = 10 per group) (C) A similar effect was observed in the
light-dark-box in mice (Series of four experiments, n = 10 per group). For all displays: mean ± SD; comparison against respective control using ANOVA with
Dunnett’s post hoc. ∗ or # p < 0.05; ∗∗ or ## p < 0.01; and the symbol “#” indicates imepitoin and “∗” indicates diazepam.
of 3.13 mg/kg and 6.25 mg/kg diazepam, a small number of
animals fell off the maze (data not shown).
In mice, after p.o. administration of 30 mg/kg imepitoin 2 h
prior to the test no effect was observed compared to placebo.
Light-Dark-Box in Rodents
The effect on the latency to the first cross to the dark part of
the box, the total amount of time spent in the light part and the
number of crosses were assessed.
In rats (n = 10 per group) imepitoin was tested in a dose
range of 1, 3, 10, and 30 mg/kg po compared to placebo
(administered 2 h before test). The latency to first cross and total
time in the light chamber were significantly increased at doses
higher than 1 mg/kg imepitoin (Table 1), however, no clear dose
dependence was observed. The number of movements between
the compartments was not significantly increased. No visible side
effects occurred within the dose range tested. For comparison,
diazepam (1, 3, 6, and 10 mg/kg oral, 30 min before test) showed
a strong anti-anxiety response in a dose-dependent manner
(Figure 2B; parameters with significant effects: latency to the first
cross, total time in the light chamber, number of crosses).
In mice (n = 10 per group), imepitoin at i.p. doses of 3
and 10 mg/kg (administered 30 min before test) significantly
prolonged the phases of staying in the light part of the two
chamber box in mice compared to placebo. The dose 10 mg/kg
additionally prolonged the latency before the mice entered for
first time the dark compartment. The dose 1 mg/kg showed no
changes compared to placebo. Diazepam (1, 3, and 10 mg/kg)
exerted its anxiolytic like activity in a dose dependent manner
(Figure 2C and Table 1).
Social Interaction Test in Rats
The effect on social interaction was assessed in pairs of unfamiliar
rats (5 groups with 9 pairs each) in unfamiliar surroundings
under high illumination. Imepitoin administered by oral gavage
once daily for four consecutive days, significantly increased social
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TABLE 1 | Results of model studies in rats and mice.
Treatment Dose Measure Statistical result Treatment Dose Measure Statistical result
Elevated Maze in Rats. Parameter: % time spent in open arms. Statistical Test: Dunnett’s procedure. N = 10 per group.
Imepitoin C 31.3 ± 14.0 F (2,27) = 1.379 Triazolam C 24.1 ± 11.19 F (2,27) = 5.392∗
1.0 39.0 ± 8.25 (ns) 0.03 40.4 ± 11.16 p < 0.05
3.0 30.9 ± 13.57 (ns) 0.1 41.6 ± 16.79 p < 0.05
C 16.7 ± 10.69 F (2,27) = 6.493∗ C 18.0 ± 11.35 F (2,27) = 0.790
10.0 33.1 ± 13.34 p < 0.01 0.3 32.6 ± 26.78 (ns)
30.0 32.7 ± 10.59 p < 0.01 1.0 27.8 ± 35.48 (ns)
Diazepam C 15.0 ± 9.3 F (4,45) = 2,633∗ Alprazolam C 19.7 ± 8.57 [see footnote]
0.25 19.2 ± 12.84 ns 0.1 20.9 ± 11.89 ns
0.5 21.9 ± 8.66 ns C 26.6 ± 9.96 F (2,27) = 3.884∗
1.0 27.4 ± 13.41 ns 0.3 35.97 ± 8.7 p < 0.05
2.0 29.4 ± 20.08 p < 0.05 1.0 27.6 ± 14.07 ns
Triazolam C 23.0 ± 14.07 F (2,27) = 1.783 Penterazol C 18.9 ± 11.07 F (2,27) = 1.631
0.003 19.7 ± 12.14 (ns) 10.0 15.6 ± 10.56 (ns)
0.01 29.4 ± 8.00 (ns) 20.0 10.4 ± 10.18 (ns)
Elevated Maze in Mice. Parameter: Entries into open arms. Statistical Test: Dunnett’s procedure. N = 10 per group.
Imepitoin C 9,8 ± 3,79 F (7,72) = 2.52∗ Diazepam C 9 ± 2,53 F (7,72) = 3.13∗
3.1 16 ± 5,69 p < 0.05 0.2 13 ± 5,38 ns
6.25 10,8 ± 3,16 ns 0.39 16,7 ± 6,96 ns
12.5 11 ± 4,11 ns 0.78 15,5 ± 6,96 ns
25 12,4 ± 4,74 ns 1.56 23,1 ± 8,85 p < 0.01
50 7,8 ± 4,43 ns 3.13 14,6 ± 11,70 ns
100 9,1 ± 8,85 ns 6.25 16,3 ± 12,65 ns
200 5,8 ± 4,74 ns 12.5 9,3 ± 8,22 ns
Light Dark in rats. Parameter: Total time in light chamber. Statistical Test: Dunnett’s procedure. N = 10 per group.
Imepitoin C 25 ± 12,6 F (4,45) = 2.866∗ Diazepam C 18 ± 10,5 F (4,45) = 14,18∗
1 29,7 ± 14,29 ns 1 41,9 ± 17,08 p < 0.05
3 44,1 ± 21,82 ns 3 62,7 ± 31,15 p < 0.01
10 47,3 ± 20,02 p < 0.05 6 79,3 ± 27,26 p < 0.001
30 45,7 ± 24,35 p < 0.05 10 100,9 ± 39,21 p < 0.001
Light Dark in mice. Parameter: Total time in light chamber. Statistical Test: Dunnett’s procedure. N = 10 per group.
Imepitoin C 98,8 ± 21,19 F (3,36) = 7,427∗ Diazepam C 87 ± 19,29 F (3,36) = 29,6∗
1 108 ± 17,39 ns 1 109 ± 26,25 ns
3 136,5 ± 24,67 p < 0.001 3 133 ± 39,84 p < 0.05
10 131 ± 19,92 p < 0.01 10 227,2 ± 49,96 p < 0.0001
Social Interaction in rats. Parameter: score points. Statistical Test: Kruskal–Wallis with Dunn’s post hoc. N = 9 pairs per group.
Imepitoin C 62.89 + 10,76 H = 16.11∗ Imepitoin 30 60.67 + 8.68 ns
3 58 + 13,26 ns Diazepam 5 70.78 + 8.18 ns
10 78.56 + 13.19 p < 0.05
Vogel Conflict Test in rats. Parameter: number of shocks received. Statistical Test: Dunnett’s procedure. N = 12 per group.
Imepitoin C 51,4 ± 26,67 F (5,66) = 9,147∗ Diazepam C 62,3 ± 22,35 F (3,44) = 6,08∗
1 61,3 ± 30,14 ns 0.3 70,9 ± 23,73 ns
3 83,2 ± 24,94 ns 1 92,1 ± 11,15 p < 0.05
10 80 ± 31,87 ns 3 104 ± 41,22 p < 0.01
30 126 ± 54,39 p < 0.0001
50 135 ± 53,69 p < 0.0001
(Continued)
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TABLE 1 | Continued
Treatment Dose Measure Statistical result Treatment Dose Measure Statistical result
Geller Conflict test in rats. Parameter: Number of punished responses. Statistical Test: Dunnett’s procedure. N = 8 per group.
Chlordiazepoxide C 1,6 ± 2,26 t = 4,078 df = 14 Imepitoin 10 2,6 ± 3,39 (ns)
16 10 ± 5,37 p < 0.01 30 2,4 ± 2,55 (ns)
Imepitoin C 2,9 ± 5,37 F (4,35) = 0,6268 Diazepam 16 5,4 ± 5,37 (ns)
3 4,6 ± 6,22 (ns)
Four Plate Test in mice. Parameter: punished crossings. Statistical Test: Dunnett’s procedure. N = 10 per group.
Imepitoin C 14.7 ± 4.74 F (7,72) = 0.99 Diazepam C 14.8 ± 7.91 F (7,72) = 3.4∗
3.13 16.1 ± 6.01 (ns) 0.2 23.1 ± 14.23 ns
6.25 17.1 ± 8.22 (ns) 0.39 27.1 ± 12.65 p < 0.05
12.5 14.9 ± 7.59 (ns) 0.78 25.7 ± 8.22 ns
25 14.0 ± 7.27 (ns) 1.56 27.7 ± 7.91 p < 0.05
50 16.6 ± 13.28 (ns) 3.13 28.2 ± 15.50 p < 0.05
100 13.9 ± 8.22 (ns) 6.25 14.7 ± 7.59 ns
200 9.2 ± 7.91 (ns) 12.5 16.4 ± 9.17 ns
Dosage “C” indicates placebo control. All measures presented as mean ± SD. For ANOVA procedures F(dFn,dFd) is reported with ∗ indicating significance (i.e., p < 0.05).
All post hoc tests were performed for differences compared to control. ns, non-significant differences. For Alprazolam 0.1 mg/kg: As this experiment was only a two group
set-up, no ANOVA could be performed. An unpaired t-test revealed no significant differences (t = 0.2589; df = 18).
interaction at 10 mg/kg compared to placebo (Table 1) but had
no significant effect on social interaction at either 3 or 30 mg/kg.
Signs of sedation were noted in some rats treated with 30 mg/kg
which may have interfered with social interaction. The positive
control, diazepam 5 mg/kg similarly administered by oral gavage
likewise increased social interaction (Figure 3A and Table 1).
Conflict-Based Tests in Rodents
The anxiolytic effect of oral imepitoin (1, 3, 10, 30, and 50 mg/kg),
diazepam (0.3, 1, and 3 mg/kg), or placebo in rats was also
investigated using the Vogel conflict test. Imepitoin exerted a
dose dependent increase in the number of shocks received, which
was significantly increased at doses of 30 and 50 mg/kg compared
to placebo (Figure 3B and Table 1). The number of shocks was
also increased for diazepam in a dose-dependent manner being
significant at doses of 1 and 3 mg/kg (Table 1).
Imepitoin (3, 10, and 30 mg/kg as oral suspension,
administered 2 h before the test) was also tested in the
Geller conflict test in rats (n = 8 in cross over design), with
chlordiazepoxide (16 mg/kg p.o. 1 h prior to test), diazepam
(16 mg/kg p.o., 2 h prior to test) and placebo for comparison.
After administration of 3 mg/kg imepitoin or 16 mg/kg
diazepam tended to increase the number of punished responses,
however, the difference did not reach statistical significance
compared to placebo. No effects were observed for 10 and
30 mg/kg imepitoin. In this study, only chlordiazepoxide after
administration of a dose exerting sedative effects (16 mg/kg)
significantly increased the number of punished responses and the
number of shocks received (Figure 3C and Table 1). Imepitoin
FIGURE 3 | (A) Treatment with 10 mg/kg imepitoin significantly increased the interaction between pairs of rats (n = 9 pairs per group). (B) An increase in the number
of punished responses in the Vogel conflict test was observed in doses above 10 mg/kg imepitoin or above 1 mg/kg diazepam (Series of three experiments, n = 12
per group). (C) No relevant effect was observed in the Geller conflict test neither for imepitoin nor for diazepam (n = 8 in cross over design). For all tests: mean ± SD.
Comparison against respective control using ANOVA with Dunnett’s post hoc.∗ or # p < 0.05; ∗∗ or ## p < 0.01 In display B, the symbol “#” indicates imepitoin and
“∗” indicates diazepam.
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did not affect the number of unpunished responses at any dose
tested, i.e., the substance did not show sedative effects.
In mice, the four plate test was used with intraperitoneal
administration of imepitoin (3.13, 6.25, 12.5, 25, 50, 100,
and 200 mg/kg), diazepam (0.2, 0.39, 0.78, 1.56, 3.13, 6.25,
and 12.5 mg/kg), and placebo administered 30 min before
the test. No effect on punished as well as on un-punished
behavior was shown for imepitoin (3.13–200 mg/kg i.p), whereas
diazepam (0.39–3.13 mg/kg i.p) significantly increased crossings
of punished plates compared to placebo (Table 1). In higher
doses, diazepam elicited sedative effects.
Noise-Induced Model of Fear and
Anxiety in Dogs
Dogs (n = 24) were tested in an open field sound-induced fear
model with exposure to artificial stimuli (thunderstorm sound)
as eliciting context and treated with a single dose of imepitoin
(20 mg/kg p.o.) 138 min before thunder exposure. Overall,
imepitoin significantly lowered the cortisol levels in 13 out of
16 dogs (81%) that were declared as cortisol responders at the
beginning of the study (Figure 4A). Both during the complete
testing period as well as during the thunder interval (minutes
4–6), total distance traveled was significantly higher during the
treatment thunder test compared to the baseline thunder test
(Figure 5 and Table 2). In addition, total inactivity frequency was
significantly higher at treatment than baseline.
Separating the dogs into hypoactive (i.e., those who reacted
at baseline with less activity in response to thunder noise) and
hyperactive (i.e., those who reacted at baseline with more activity
in response to thunder noise), in both groups (n = 12 each)
an increase in distance traveled and inactivity frequency was
observed. However, the effect was larger for the hypoactive dogs
and was significant in this subgroup only (distance traveled:
p < 0.001 in paired t-test; inactivity frequency: p < 0.05).
In contrast, in a separate experiment dogs (n = 25) treated
with dexmedetomidine applied as oromucosal gel showed a
significantly decreased total distance traveled (Figure 5 and
Table 2). Dexmedetomidine showed no relevant effect on cortisol
levels in dogs that were declared as cortisol responders at the
beginning of the study (Figure 4B and Table 2).
DISCUSSION
Imepitoin was tested in a battery of standard preclinical tests
for anxiety behavior. The observed profile appears typical
for anxiolytic drugs (Andrews et al., 2014). Based upon the
performance of imepitoin in these standard tests designed to
evaluate potential anxiolytic activity, it can be concluded that
imepitoin has anxiolytic properties similar to benzodiazepines.
In an in vitro model, imepitoin was capable of preventing
the effect of CRF on LC neurons without suppressing the basal
activity of these cells, an activity which is suggestive for an
anti-stress effect of imepitoin (Valentino et al., 1993).
Ethological test paradigms rely on stimulated forms of anxiety
within the normal range. The elevated-plus-maze for example is
based on small rodent’s avoidance of open, bright areas due to
the higher risk of predator attacks (Hogg, 1996; Rodgers et al.,
1997). Especially the elevated-plus maze appears to be sensitive to
positive GABA modulating agents, while other substance classes
like for example α2-agonists (e.g., dexmedetomidine) showed no
effect in this test (Salonen et al., 1992). The social interaction
test reflects the uncertainty in meeting unknown individuals in
unfamiliar environments, and this ethologically natural paradigm
can be used to examine social avoidance (File and Seth, 2003). In
all of the tests applied, imepitoin showed comparable responses
to diazepam, however, at higher doses. This observation supports
the notion that imepitoin acts as a partial agonist.
In addition, conflict-based tests were used, measuring
anxiolytic-like activity as the maintenance of a behavioral
FIGURE 4 | In an open field noise-induced fear model (i.e., exposure to thunderstorm noises) serum cortisol values were measured 60 min before and 5 min after
exposure to noise. (A) In a first experiment (n = 12), single dose imepitoin treatment (20 mg/kg) was compared to baseline. (B) The same setup was independently
repeated (n = 25) with a single dose of dexmedetomidine. Mean ± SD; ∗p < 0.05; ∗∗p < 0.01; and ∗∗∗p < 0.001 in ANOVA with Sidak’s post hoc.
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FIGURE 5 | In the two independent noise-induced fear model experiments, a
single dose of imepitoin (20 mg/kg; n = 12; left) elicited an increase in distance
traveled compared to baseline, while a single dose of dexmedetomidine
(125 µg/m2; n = 25; right) resulted in a decrease compared to baseline.
Boxplot with whiskers according to Tukey’s procedure and “+”indicating the
mean; ∗∗∗p < 0.001 in paired t-test.
response (for example, licking or bar pressing) despite the receipt
of a mild electric shock. Anxiolytic action in these tests is
generally defined as maintenance of responding in the presence of
the punishing stimulus since this would override the inhibition.
Interpretation of the results appears difficult under the premise
that disinhibition alone is not per se an anxiolytic action, and
analgesic effects of a test compound could produce similar effects
simply by inhibiting pain reactions to the punishment (Andrews
et al., 2014). In the Geller conflict test a large variability in
response to certain benzodiazepines is described in the literature
(Babbini et al., 1982). Regardless, conflict situations with two
opposing impulses are a component of anxiety disorders, and
conflict based tests are still widely applied to screen for anxiolytic
drug candidates. Imepitoin showed only a significant effect in
the Vogel conflict test, but not in the Geller conflict test or the
four plate test. Apparently imepitoin has no strong disinhibition
component and does not result in irrational risk taking.
We observed anxiolytic activity also in dogs in a provoked
open field sound-induced fear model, where reactions to noises
were elicited by a sound recording of thunderstorms. While
tests like these are considered to have a good test–retest
reliability, the generalizability to patients relating to changes in
locomotion and exploratory behavior observed under anxiolytic
treatment underlies the general limitations of a model (Wormald
et al., 2016). We observed an increase in locomotion measured
in distance traveled after imepitoin treatment. In addition,
dogs paused their activity more often under treatment, which
might indicate an interruption of their current behavior to
assess their environment (McNaughton and Gray, 2000). After
dexmedetomidine treatment, which was shown to have anxiolytic TA
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effects in dogs (Korpivaara et al., 2017), we observed a decrease in
locomotion. This is not a surprising result as dexmedetomidine,
and other α2-adrenoceptor agonists, are widely used as
premedication to induce anesthesia (Beckman, 2013) and
sedative effects were already described for transmucosal
administration in dogs (Cohen and Bennett, 2015). For
comparison, the effect of benzodiazepines in this model is
associated with an increase in exploratory behavior, which is also
measured as increase in total distance traveled (Wormald et al.,
2016). Due to the highly controlled conditions, the changes in
behavior in the imepitoin or dexmedetomidine groups compared
to baseline are most plausibly explained by the treatment.
Cortisol as a stress hormone indicative of arousal plays a
role in anxiety disorders. For example, dogs with noise phobia
suffer from severe mental stress evidenced by an inability to
relax and cortisol levels in these dogs increasing more than
twofold during thunderstorms (Dreschel and Granger, 2005).
In addition, dogs with noise phobia have higher cortisol levels
in their hair (Siniscalchi et al., 2013). In our hands, we
observed an ameliorating effect of imepitoin on cortisol levels in
response to thunderstorm noises, but not for dexmedetomidine.
Benzodiazepines were found to suppress cortisol levels (Manthey
et al., 2010), and thus these findings further support the
benzodiazepine-like anxiolytic effect of imepitoin.
A relevant limitation of the suite of studies presented
here is the use of different dosages and administration routes
across studies. While the different dosages were chosen based
on the stage of the development program reported here,
it complicates comparison between the models and allows
no definitive conclusions on the optimal dose. Notably, the
logistical need for separate independent experiments due to
the large number of groups limits the comparison between
treatments and between independent experiments to a qualitative
assessment. In addition, the conclusion of an anxiolytic effect
is based on the similar performance to benzodiazepines in
standard models of anxiety, which needs validation in clinical
trials.
In all animal models the imepitoin doses needed for an
anxiolytic effect were not associated with sedation. In rodents,
there was at least a factor of 10 between anxiolytic doses and
doses with mild signs of sedation. In the dog model, treatment
with imepitoin resulted in increased locomotion.
CONCLUSION
In conclusion, imepitoin showed anxiolytic properties similar
to benzodiazepines in various standard models for anxiety
behavior but without producing the known adverse reactions of
benzodiazepines such as sedation, without evidence of behavioral
inhibition in the situations explored. Accordingly imepitoin
appears to be a promising candidate for treating anxiety
disorders, and first data in dogs with anxiety problems showed
promising results for therapeutic use of imepitoin in canine
anxiety disorders (McPeake and Mills, 2017).
AVAILABILITY OF DATA AND MATERIAL
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, to
any qualified researcher.
AUTHOR CONTRIBUTIONS
All authors had access to all the study information, raw
data, and approved the manuscript. CR led the conduct and
evaluation of rodent models. DM, OE, GL, and AM contributed
to the conception, design of the dog anxiety model, and the
interpretation of the results. AM and MB conducted and
evaluated the dog open field studies. OE prepared the manuscript
with support of all authors.
FUNDING
The study was funded by Boehringer Ingelheim Vetmedica
GmbH.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphar.
2018.01225/full#supplementary-material
REFERENCES
Andrews, N. A., Papakoste, M., and Barmes, N. M. (2014). Discovery of novel
anxiolytic agents — The trials and tribulations of pre-clinical models of anxiety.
Neurobiol. Dis. 61, 72–78. doi: 10.1016/j.nbd.2013.10.006
Araujo, J. A., De Rivera, C., Landsberg, G. M., Adams, P. E., and Milgram, N. W.
(2013). Development and validation of a novel laboratory model of sound-
induced fear and anxiety in Beagle dogs. J. Vet. Behav. Clin. Appl. Res. 8,
204–212. doi: 10.1016/j.jveb.2012.10.008
Babbini, M., Gaiardi, M., and Bartoletti, M. (1982). Benzodiazepine effects
upon geller-seifter conflict test in rats: analysis of individual variability.
Pharmacol. Biochem. Behav. 17, 43–48. doi: 10.1016/0091-3057(82)
90260-X
Beckman, B. (2013). Anesthesia and pain management for small animals. Vet. Clin.
North Am. 43, 669–688. doi: 10.1016/j.cvsm.2013.02.006
Bourin, M., and Hascoet, M. (2003). The mouse light/dark box test. Eur. J.
Pharmacol. 463, 55–65. doi: 10.1016/S0014-2999(03)01274-3
Cohen, A. E., and Bennett, S. L. (2015). Oral transmucosal administration of
dexmedetomidine for sedation in 4 dogs. Can. Vet. J. 56, 1144–1148.
Dreschel, N. A., and Granger, D. A. (2005). Physiological and behavioral reactivity
to stress in thunderstorm-phobic dogs and their caregivers. Appl. Anim. Behav.
Sci. 95, 153–168. doi: 10.1016/j.physbeh.2017.04.008
File, S. E., and Hyde, J. R. (1978). Can social interaction be used to measure anxiety?
Br. J. Pharmacol. 62, 19–24.
File, S. E., and Seth, P. (2003). A review of 25 years of the social
interaction test. Eur. J. Pharmacol. 463, 35–53. doi: 10.1016/S0014-2999(03)
01273-1
Geller, I., and Seifter, J. (1960). The effects of meprobamate, barbiturates,
d-amphetamine and promazine on experimentally induced conflict in the rat.
Psychopharmacologia 1, 482–492. doi: 10.1007/BF00429273
Frontiers in Pharmacology | www.frontiersin.org 10 November 2018 | Volume 9 | Article 1225
fphar-09-01225 October 30, 2018 Time: 15:20 # 11
Engel et al. Imepitoin in Models of Anxiety
Griebel, G., and Holmes, A. (2013). 50 years of hurdles and hope in anxiolytic drug
discovery. Nat. Rev. Drug Discov. 12, 667–687. doi: 10.1038/nrd4075
Hogg, S. (1996). A review of the validity and variability of the elevated plus-
maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54, 21–30.
doi: 10.1016/0091-3057(95)02126-4
Jones, G. H., Schneider, C., Schneider, H. H., Seidler, J., Cole, B. J., and
Stephens, D. N. (1994). Comparison of several benzodiazepine receptor ligands
in two models of anxiolytic activity in the mouse: an analysis based on
fractional receptor occupancies. Psychopharmacology 114, 191–199. doi: 10.
1007/BF02244836
Korpivaara, M., Laapas, K., Huhtinen, M., Schöning, B., and Overall, K. (2017).
Dexmedetomidine oromucosal gel for noiseassociated acute anxiety and fear in
dogs—a randomised, double-blind, placebo-controlled clinical study. Vet. Rec.
180:356. doi: 10.1136/vr.104045
Liss, B., Bruns, R., and Roeper, J. (1999). Alternative sulfonylurea receptor
expression defines metabolic sensitivity of K-ATP channels in dopaminergic
midbrain neurons. EMBO J. 18, 833–846. doi: 10.1093/emboj/18.4.833
Löw, K., Crestani, F., Kleist, R., Benke, D., Brünig, I., Benson, J. A., et al. (2000).
Molecular and neuronal substrate for the selective attenuation of anxiety. Sci.
Prog. 290, 131–134.
Manthey, L., Giltay, E. J., Van Veen, T., Neven, A. K., Vreeburg, S. A.,
Penninx, B. W., et al. (2010). Long-term benzodiazepine use and salivary
cortisol: the Netherlands Study of Depression and Anxiety (NESDA). J. Clin.
Psychopharmacol. 30, 160–168. doi: 10.1097/JCP.0b013e3181d41f41
McNaughton, N., and Gray, J. A. (2000). Anxiolytic action on the behavioural
inhibition system implies multiple types of arousal contribute to anxiety.
J. Affect. Disord. 61, 161–176. doi: 10.1016/S0165-0327(00)00344-X
McPeake, K. J., and Mills, D. S. (2017). The use of imepitoin (Pexion) on fear
and anxiety related problems in dogs - a case series. BMC Vet. Res. 13:173.
doi: 10.1186/s12917-017-1098-0
Millan, M. J., and Brocco, M. (2003). The Vogel conflict test: procedural aspects,
gamma-aminobutyric acid, glutamate and monoamines. Eur. J. Pharmacol. 463,
67–96. doi: 10.1016/S0014-2999(03)01275-5
Rodgers, R. J., Cao, B.-J., Dalvi, A., and Holmes, A. (1997). Animal models
of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30, 289–304.
doi: 10.1590/S0100-879X1997000300002
Rundfeldt, C., Gasparic, A., and Wlaz, P. (2014). Imepitoin as novel treatment
option for canine idiopathic epilepsy: pharmacokinetics, distribution, and
metabolism in dogs. J. Vet. Pharmacol. Ther. 37, 421–434. doi: 10.1111/jvp.
12117
Rundfeldt, C., and Loscher, W. (2014). The pharmacology of imepitoin: the first
partial benzodiazepine receptor agonist developed for the treatment of epilepsy.
CNS Drugs 28, 29–43. doi: 10.1007/s40263-013-0129-z
Salonen, M., Onaivi, E. S., and Maze, M. (1992). Dexmedetomidine synergism
with midazolam in the elevated plus-maze test in rats. Psychopharmacology 108,
229–234. doi: 10.1007/BF02245313
Sigel, E., Baur, R., Netzer, R., and Rundfeldt, C. (1998). The antiepileptic drug
AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A)
receptor through the benzodiazepine binding site. Neurosci. Lett. 245, 85–88.
doi: 10.1016/S0304-3940(98)00186-4
Siniscalchi, M., Mcfarlane, J. R., Kauter, K. G., Quaranta, A., and Rogers, L. J.
(2013). Cortisol levels in hair reflect behavioural reactivity of dogs to acoustic
stimuli. Res. Vet. Sci. 94, 49–54. doi: 10.1016/j.rvsc.2012.02.017
Skolnick, P. (2012). Anxioselective anxiolytics: on a quest for the Holy Grail. Trends
Pharmacol. Sci. 33, 611–620. doi: 10.1016/j.tips.2012.08.003
Stein, M. B., and Steckler, T. (2010). Behavioral Neurobiology of Anxiety and Its
Treatment. Heidelberg: Springer. doi: 10.1007/978-3-642-02912-7
Valentino, R. J., Foote, S. L., and Page, M. E. (1993). The Locus Coeruleus as a Site
for integrating corticotropin-releasing factor and noradrenergic mediation of
stress responsesa. Ann. N. Y. Acad. Sci. 697, 173–188. doi: 10.1111/j.1749-6632.
1993.tb49931.x
Walf, A. A., and Frye, C. A. (2007). The use of the elevated plus maze as an assay of
anxiety-related behavior in rodents. Nat. Protoc. 2, 322–328. doi: 10.1038/nprot.
2007.44
Whiting, P. J. (2006). GABA-A receptors: a viable target for novel anxiolytics? Curr.
Opin. Pharmacol. 6, 24–29. doi: 10.1016/j.coph.2005.08.005
Wormald, D., Lawrence, A. J., Carter, G., and Fisher, A. D. (2016). Validation of
modified open field behaviour as a measure of trait anxiety in the dog. Appl.
Anim. Behav. Sci. 179, 95–102. doi: 10.1016/j.applanim.2016.03.004
Conflict of Interest Statement: This publication followed the GPP3 guidelines.
OE is an employee of Boehringer Ingelheim Vetmedica GmbH, Germany, the
marketing authorization holder of Pexion R©, containing Imepitoin as active
principle. CR and DM acted as consultants for Boehringer Ingelheim.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Engel, Masic, Landsberg, Brooks, Mills and Rundfeldt. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 November 2018 | Volume 9 | Article 1225
